Login / Signup

Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.

Senthil DamodaranFengmin ZhaoDustin A DemingEdith P MitchellJohn J WrightRobert C GrayVictoria WangLisa Meier McShaneLawrence V RubinsteinDavid R PattonP Mickey WilliamsStanley R HamiltonJennifer M SugaBarbara A ConleyCarlos L ArteagaLyndsay N HarrisPeter J O'DwyerAlice P ChenKeith T Flaherty
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
mutation in the refractory setting.
Keyphrases
  • phase ii study
  • open label
  • phase iii
  • phase ii
  • study protocol
  • locally advanced
  • clinical trial
  • placebo controlled
  • randomized controlled trial
  • rectal cancer
  • protein kinase
  • double blind
  • radiation therapy